Market revenue in 2023 | USD 360.6 million |
Market revenue in 2030 | USD 584.8 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 94.43% in 2023. Horizon Databook has segmented the Italy hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
Recently, Italy experienced a rapid evolution in prenatal screening for fetal chromosome abnormalities. This includes replacement of combined or triple test by sequential modalities and technologies based on cell-free DNA, which has improved detection of abnormalities while diminishing the need for invasive testing.
The increasing popularity of NIPTs potentially overcomes challenges witnessed during invasive prenatal diagnosis, as NIPT can be provided to all pregnant women regardless of their age.
A recent study by Chiara Palka et al. published in July 2019, discussed the paradigm shift from invasive prenatal diagnosis to NIPT in Italy. Their findings revealed that evolution of prenatal screening impacted utilization of invasive prenatal diagnosis.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Italy hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account